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Abstract
Background: N-of-1 (individual comparison) trials are a promising approach for comparing the effectiveness of 2 or more
treatments for individual patients; yet, few studies have qualitatively examined how patients use and make sense of their own
patient-generated health data (PGHD) in the context of N-of-1 trials.
Objective: The objective of our study was to explore chronic pain patients’ perceptions about the PGHD they compiled while
comparing 2 chronic pain treatments and tracking their symptoms using a smartphone N-of-1 app in collaboration with their
clinicians.
Methods: Semistructured interviews were recorded with 33 patients, a consecutive subset of the intervention group in a primary
study testing the feasibility and effectiveness of the Trialist N-of-1 app. Interviews were transcribed verbatim, and a descriptive
thematic analysis was completed.
Results: Patients were enthusiastic about recording and accessing their own data. They valued sharing data with clinicians but
also used their data independently.
Conclusions: N-of-1 trials remain a promising approach to evidence-based decision making. Patients appear to value their roles
as trial participants but place as much or more importance on the independent use of trial data as on comparative effectiveness
results. Future efforts to design patient-centered N-of-1 trials might consider adaptable designs that maximize patient flexibility
and autonomy while preserving a collaborative role with clinicians and researchers.
(JMIR Mhealth Uhealth 2018;6(10):e10291) doi: 10.2196/10291
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Introduction
Evidence-based medicine, as described by Sackett et al (1996),
is “the conscientious, explicit, and judicious use of current best
evidence in making decisions about the care of individual
patients” [1]. At the top of the evidence hierarchy are
randomized controlled trials (RCTs) and meta-analyses of RCTs
[2]. However, even when such evidence is available, applying
it to an individual patient in clinical practice is not always
straightforward [3].
Even the highest quality RCTs and meta-analyses can only
estimate the average effect of a treatment from a group of trial
participants [4]. Because there is inherent heterogeneity in the
effects of any treatment (ie, individuals within a population
experience differences in the magnitude and direction of
treatment and side effects), the average effect estimated in an
RCT is not always applicable to an individual patient [4,5]. The
uncertainty around applying such evidence may be particularly
salient when patients have attributes (eg, complex medical or
social circumstances) that differentiate them from an average
RCT participant. Several studies have convincingly
demonstrated that typical patients in many RCTs (ie, those at
the 50th percentile for risk of poor outcomes) differ greatly from
and often receive much less benefit than the average patients
[3]. Therefore, investigators have sought methods that bring
evidence-based practice closer to Sackett’s ideal [1,5].
N-of-1 trials are individualized crossover trials that may help
to address this dilemma by comparing the effectiveness of 2 (or
more) treatments for an individual patient [6]. N-of-1 trials have
the potential to improve clinical decision making in several
ways; for example, they can be conducted in a “real world”
environment—with clinically complex patients who would
likely not meet the stringent inclusion criteria of a traditional
RCT—and adapted with individualized protocols that consider
the needs and preferences of patients and clinicians [5-7].
Despite many potential advantages, N-of-1 trials are infrequently
used in health care [5], partly because of inherent limitations
of the method. They are as follows. N-of-1 trials are only
applicable to chronic, nonfatal conditions and to treatments with
rapid onset and washout. In addition, the appeal of N-of-1 trials
has been limited by several external factors including cost, lack
of external funding opportunities, and the substantial time
investment required from both clinician and patient [5].
Some of these logistical barriers may be overcome with the
usage of mHealth technology to collect and synthesize
patient-generated health data (PGHD). PGHD is defined as
“health-related data created, recorded, or gathered from and by
patients (or family members or other caregivers) to help address
a health concern” [8]. The explosion of wearables and mHealth
technology apps designed to collect and manage PGHD may
provide an approach to N-of-1 trial data collection that eases
participant burden while providing valuable information that
informs decision making and improves patients’ understanding
of their own symptoms and treatments.
Patients appear to value and use PGHD obtained from mHealth
and wearable technologies. However, few studies have examined
http://mhealth.jmir.org/2018/10/e10291/
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patients’ experience with PGHD in the N-of-1 trial setting
[7,9,10]. In a study that examined theoretical barriers and
facilitators to N-of-1 trial adoption, patients with chronic
conditions expressed enthusiasm for the N-of-1 trial concept
[7]. In particular, patients appeared to value the idea of having
individualized results and felt that participation would have
other likely benefits such as more rigorous self-monitoring of
symptoms and side effects [7]. However, patients also expressed
concerns about potential safety issues and skepticism around
feasibility, given the already busy schedules of clinicians and
lives of patients [7]. Two previous studies that qualitatively
examined perspectives of N-of-1 trial participants reported that
patients were largely satisfied with their N-of-1 trial experience
and that participation increased self-awareness of their medical
condition [9,10]. However, both studies were based in the United
Kingdom and neither reported on N-of-1 trials that included an
mHealth component.
In this study, we extend prior knowledge by exploring patients’
experiences in monitoring their own symptoms and collaborating
with primary care providers to use PGHD resulting from
mHealth supported N-of-1 trials for chronic pain management.
Our findings shed light on ways in which patients make sense
of and use their health data in partnership with clinicians to
inform treatment decisions in the N-of-1 trial context. Results
of our work may inform targeted patient education, shared
decision making, and self-management interventions to improve
chronic pain. In addition, our findings have important
implications for patient-centered design and implementation of
mHealth technology–enabled N-of-1 trials.

Methods
Design and Setting
This qualitative study was embedded within a randomized
controlled trial, Personalized Research for Monitoring Pain
Treatment (PREEMPT), which examined the effectiveness of
using a mobile pain software app for conducting single-patient
crossover (“N-of-1”) trials among patients with chronic
musculoskeletal pain. Members of our team collaborated with
the nonprofit mHealth developer Open mHealth to create the
app, called Trialist, to promote tracking and summarizing of
chronic pain symptoms using a smartphone. The Trialist app
allows tracking of chronic pain symptoms over time while also
providing graphical summaries of results of N-of-1 comparative
trials.

The Personalized Research for Monitoring Pain
Treatment Study
Details of the PREEMPT study design are reported elsewhere
[11]. Briefly, a sample of primary care clinicians and their
chronic pain patients were recruited. Patients were randomized
to the Trialist app intervention or usual care. Both Trialist app
intervention and usual care groups had multiple variables
measured at baseline and at 3, 6, and 12 months through
self-administered questionnaires. Questions assessed pain
intensity, pain interference, medication adherence,
medication-related shared decision making, pain treatment
satisfaction, and general health-related quality of life.
JMIR Mhealth Uhealth 2018 | vol. 6 | iss. 10 | e10291 | p. 2
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Figure 1. Example of patients’ view within the app.

Intervention patients were provided free access to the app for
use on their mobile device (iOS or android). These patients
collaborated with their clinicians to create single-patient
crossover (N-of-1) trials. In setting up the N-of-1 trial, the
patient and clinician would jointly determine treatments to
compare length of time for each treatment (1 or 2 weeks) and
the number of times the patient would switch between treatment
A and B (2, 3, or 4); for example, a patient might use treatment
A for 2 weeks and then switch to treatment B for 2 weeks, then
A again for 2 weeks, and then B again. For comparison, the
following 8 treatment categories were available: acetaminophen;
any nonsteroidal anti-inflammatory drug; opioid combination
product with codeine; opioid combination product with
hydrocodone; opioid combination product with oxycodone;
tramadol; complimentary or alternative treatments such as
massage, meditation, or physical exercise; and current ongoing
therapy (or no therapy). The following 2 types of PGHD were
produced during the trial: tracking data and summary data (ie,
comparative results).

Tracking Data
Intervention patients were queried weekly on their adherence
to their assigned treatment over the previous 7 days. They were
prompted to use the app to provide daily symptom reports on
3 dimensions of pain—pain on average, pain interference with
enjoyment of life, and pain interference with daily activities of
living. Participants also received daily prompts to report on the
following 5 potential side effects of treatment: drowsiness,
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fatigue, constipation, sleep problems, and cognitive impairment.
Patients could enter text as part of their regular reporting. They
could view these symptom and side effect reports as simple
time line graphs, as seen in Figure 1, anytime during and after
their N-of-1 trial. These daily and weekly reports from
intervention patients constituted their own tracking data. The
example graph in Figure 1 shows trends in patient-reported pain
and sleep problems.

Summary Data
Treatment comparison data were made available at the end of
a trial. At that time, results comparing the 2 treatments could
be viewed by both patient and clinician during a results review
visit. Results were presented in 6 different graphical displays;
3 graphs focused on changes in pain intensity over the N-of-1
trial (Figures 2, 3, and 4), 1 bar graph compared Treatments A
and B for pain intensity and side effects (Figure 5), and the final
2 graphs provided estimates of changes in the effect and the
probability that one treatment was better than another (Figure
6 and 7). These graphs displaying participants’ summary data
were the basis on which patients and clinicians evaluated their
N-of-1 trial results, as seen in Figure 2.
For this study, a sample of patients was interviewed after the
results review visit about their use of the Trialist app and their
experiences with their own PGHD including the tracking data
compiled from participants’ daily and weekly reports and
summary data displayed at the end of an N-of 1 trial. We report
on those patient interviews.
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Figure 2. Pain intensity chronology (zero is no pain).

Figure 3. Pain intensity by treatment (zero is no pain).
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Figure 4. Pain intensity average (zero is no pain).

Figure 5. Averaged secondary outcomes (shorter bar is better outcome).
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Figure 6. Estimated difference between treatments (bars represent margins of error).

Figure 7. Likelihood that one treatment is better than the other.
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Data Collection and Analysis
The research team designed this qualitative study once the larger
study was underway. A patient interview guide was developed.
The semistructured interview consisted of questions and
open-ended prompts, which were designed to assess the usability
and acceptance of the Trialist app, understanding of
individualized (N-of-1) study results, preferences for
presentation of summary data, and perceptions about PGHD
and the process of compiling it.
A consecutive sample of patients from the intervention group
was invited to participate in qualitative interviews from February
2016 to September 2016, an 8-month period within the parent
study, which lasted from May 2014 to April 2017. Patients were
invited at randomization, and those who had completed the
N-of-1 trial and were scheduled for a results review visit were
interviewed separately from their collaborating clinician.
Interviews were completed immediately following the results
review visits, which took place an average of 31 days after
completing the N-of-1 trial. Because qualitative interviews were
designed when the study was already underway, not all
potentially eligible patients completed N-of-1 trials and results
review visits during the interview period.
Institutional Review Board approval was obtained from
University of California, Davis (#496804) and Veterans Affairs,
Northern California Health Care System (#13-12-00717) for
all aspects of the study, including a modification for these patient
interviews that had not been part of the original study design.

Whitney et al
Interview data were organized using Dedoose Version 7.1.3
(Los Angeles, CA: SocioCultural Research Consultants,
LLC). A descriptive thematic analysis was conducted to identify
themes related to patient experiences and perceptions. Repeated
reading and analyst triangulation were employed to enhance
the quality and validity of themes [12,13]. Sociodemographic
characteristics of the interviewed patients were obtained from
data collected for the main PREEMPT trial. During their
interviews, patients were asked to self-report any background
in mathematics, statistics, engineering, science, or health care
(yes or no). The research team explored whether there were
apparent differences in patient experiences or preferences related
to this background.

Results
Patient Characteristics
Overall, 215 patients with chronic musculoskeletal pain were
randomized into the RCT. Altogether, 107 control group patients
received usual care and 108 intervention patients were supplied
with the Trialist app; 10 patients in the intervention group did
not start a trial, and 3 patients stopped the trial too early to have
any results. The remaining 95 patients completed their planned
N-of-1 trials. Of these, 80 completed an in-person results review
visit, 2 patients used an electronic patient portal for the
discussion with the clinician, and 13 patients received N-of-1
trial results by mail.

Table 1. Sociodemographic characteristics of Personalized Research for Monitoring Pain Treatment participants who participated in qualitative
interviews (N=33).
Characteristic

Participants

Age (years), mean (SD)

55 (10)

Sex, n (%)
Female

15 (45)

Male

18 (55)

Race or ethnicity, n (%)
White, non-Hispanic

22 (66)

Black, non-Hispanic

3 (9)

Asian, non-Hispanic

1 (3)

Hispanic or Latino

5 (15)

Other

2 (6)

Highest completed education, n (%)
High school diploma or equivalent (general educational development)

1 (3)

Some college (associate’s degree or vocational training)

16 (48)

College degree (bachelor of arts and bachelor of science)

8 (24)

Graduate degree

8 (24)

Self-reported background in math, statistics, engineering, science or health care, n (%)

19 (58)

Married, n (%)

20 (61)

Employed (full or part time), n (%)

16 (48)
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During the qualitative interview period, 46 patients were
randomized to the intervention group. Of these, 33 patients were
interviewed after their results review visit, 5 potentially eligible
intervention patients did not start a trial, 6 did not consent to
the interview, and 2 consented but did not complete the
interview. The demographics of the 33 interviewed patients are
displayed in Table 1.

Whitney et al
From our analysis, 3 major themes emerged with subthemes
for each. The themes are summarized along with illustrative
quotations in Textbox 1.
1.
2.
3.

Patients were enthusiastic about accessing their PGHD.
Patients found value in sharing data with their clinicians.
Patients engaged energetically in using their own data for
a wide range of purposes, some apart from those anticipated
by investigators.

Textbox 1. Summary of themes and subthemes with illustrative quotations in italics.
1.

Accessing Data
a.

b.

c.

Value of tracking data
•

I think that documenting it was the most helpful.

•

The most important factor for me was the diary.

Simplicity of presentation
•

These are too confusing for me...I want simple.

•

It’s like homework...I don’t think so.

Alternatives to data presentation
•

2.

Sharing Data
a.

b.

Patient-clinician relationship
•

We [patient and clinician] had a nice interchange about elaborating on why the results were the way they were. You can only do that
sitting side by side together.

•

She [the clinician] gets to know how my feet are truly feeling.

Confusion about data analysis
•

3.

I would like to see a little person—maybe some more pictures...I mean I understand the bars, but I get excited when I see a little girl
riding a bike or somebody going up an [in]cline [to represent changes in pain].

She [the clinician] had no idea what the graphs meant.

Using Data
a.

Noticing: increasing self-awareness
•

b.

c.

I think documenting it was most helpful because then I could see how many days I’d been a space cadet.

Deciding: drawing conclusions and correlations
•

[The app] helped me draw my own conclusions.

•

I guess it just made you pause...think about your day. What you did. How it felt. Those things, on a daily basis, I think it is a useful
exercise in pain management.

•

Well, I was confused until he [the clinician] explained it...The clinician [was the most influential factor in making a treatment decision].

Acting: self-management
•

I was also accountable when I wrote notes when I could say I didn’t do this or I didn’t do that or if that increased my fatigue...it made
me think about what could be causing some other things and if I needed to address it.

•

It let me play around with do I need one [medication dose], do I need to take two, do I need to take ‘em six hours apart, do I need to
take ‘em eight hours apart.

•

Door number three, that I came up with, worked better...the last half of the trial I was on Plan C [his own plan].
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Accessing Data
Value of Tracking Data
Nearly all interviewed patients expressed enthusiasm about
having access to their tracking data. They valued having
recorded data as well as its presence in a format to which they
could refer. “[T]he most important factor for me was the diary,”
said one respondent (female, 50s), whereas another said, “I think
that documenting it was the most helpful...” (female, 70s). A
patient (male, 40s) who stated he had “a little TBI (traumatic
brain injury)” credited the tracking as a memory aide.

Simple Presentations of Summary Data
Critically for the N-of-1 context in which treatment comparisons
were to be made, a majority of respondents preferred simple
presentations of summary data. A variety of graphical
presentations of data summarizing trial results were provided
to patients and clinicians at the results review visit. As part of
the patient interview, respondents were asked which graphs
they preferred. Of 33 patients in this subsample, 42% (14/33)
did not identify themselves as having a background in
mathematics, engineering, science, or the health professions
(Table 1), but even those who did (19/33, 58%) expressed
preference for simple data presentations of N-of-1 trial results.
In choosing which graph was the most helpful to them in making
a treatment decision, just over half of patients (16/30, 53%)
found either Figure 6 or 7—the two summary graphs that
included information about effect size and statistical
uncertainty—least helpful for decision making, as seen in
Figures 2-7. A footnote to each graph in Figures 2-7 displays
the number of interviewees (of 30 who responded to this
question) who endorsed that graph as either the most or least
helpful in making a treatment decision.
One patient requested that clinicians “spare the patient” the
work of complex interpretation of graphs. Another suggested
that patients would lose interest in an array of data: “Keep it to
the point” (male, 50s). Another interviewee said the following
in reference to the more statistically oriented graphs, as seen in
Figures 6 and 7: “These are too confusing to me...I want simple”
[male, 40s].
Referring to one of the graphs (Figure 6), a respondent said “It’s
like homework. I don’t think so” [female, 70s].

Alternative App Designs
Many patients proposed a number of innovative suggestions
for alternative ways to design the app and showed a range of
preferences for data presentation; for example, one respondent
(female, 50s) wanted to be able to track more than one pain
source, whereas another (female, 50s) suggested creating a link
to pain management tips when pain scores were high. Patients
suggested changes in the app’s design to increase their own
motivation to input their data—one respondent (female, 40s)
suggested adding graphics, specifically a bicycle going up a
hill, to illustrate effort and progress. Another (male, 60s)
suggested varying questions’ order to prevent rote and
unthinking responses to repeated queries about pain-related
symptoms such as fatigue:
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When the questions are repetitive, people tend to know
exactly what to hit every single day and it’s done.
They shoulda come up with different questions that
meant the same, but would make the person read ‘em,
instead of knowing what to put, if I’m being honest.
Some respondents wanted compression of data, whereas others
sought more detail.

Sharing Data
Value to Patient-Clinician Relationship
Patients were questioned about the format for results of review
visits with clinicians and asked if email or phone visits to review
the N-of-1 trial results summary data would have been as
satisfactory as an in-person visit. Most respondents preferred
to meet in person with clinicians to discuss results. One patient
with a high level of statistical knowledge stated,
We [patient and clinician] had a nice interchange
about elaborating on why the results were the way
they were. You can only do that looking at it
side-by-side together. [male, 70s]
Another, without statistical expertise, explained a preference
for face-to-face contact saying, “It’s easier to have a discussion
and ask questions if someone’s right in front of you” [female,
50s].
Some patients specifically reported that they engaged their
clinicians more effectively when they could back up symptom
reporting with summary data. A patient (male, 40s) engaged in
an appeal for disability services was enthusiastic about graphed
data that would provide “...proof that–for my appeal–to have
proof of a graph.” Another (male, 50s) suggested that the
tracking data generated in real time added credibility to
communication with the clinician: “She [the clinician] gets to
know how my feet are truly feeling.”
Another (female, 50s) was able to collect data on the symptom
that troubled her the most (constipation) and bring it to the
clinician’s attention as they studied trial results together. Others
reported improved relationships with their clinicians from
engaging in the N-of-1 trials using PGHD.

Understanding Data Analysis
A few patients admitted their lack of understanding about data
analysis. In the portion of the interview reviewing data analysis
for the N-of-1 trial, 2 patients relied on the staff interviewer to
clarify N-of-1 data. One (female, 70s) exclaimed, upon viewing
graphs not previously viewed with the clinician, “Oh, these are
cool...I never read this. ” After the interviewer briefly explained
the data, another respondent (male, 50s) said that the data had
been “confusing, but once it’s explained...”
Some respondents perceived that their clinicians were also
uncertain about data analysis. Several patients reported that
their clinicians did not look at the graphical summary data
during the results review visit. Some patients reported that their
clinicians had limited interest in PGHD, and a few suggested
that clinicians, like themselves, might not have understood the
data summaries. While reporting that his clinician did not refer
to summary graphs, a patient (male, 60s) stated that the clinician
JMIR Mhealth Uhealth 2018 | vol. 6 | iss. 10 | e10291 | p. 9
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had admitted that she did not understand them: She [the
clinician] had no idea what the graphs meant.

meant, reported that the clinician’s input was the main factor
in deciding which treatment was better:

Several respondents suggested that adding text explanations to
summary graphs would have facilitated interpretation,
presumably for both patients and clinicians.

Well, I was confused until he [the clinician] explained
it...The clinician [was the most influential factor in
making a treatment decision]. [female, 50s]

Using the Data

Acting: Self-Management

Noticing

Most patients used the tracking data to guide self-management.
One (male, 40s) reported that he would not have tried an
alternative treatment without the app. Another (male, 50s)
suggested a higher level of accountability for health behavior
from documenting:

Overwhelmingly, patients reported noticing what they had not
noticed before from daily reporting of their symptoms. One
patient said “I think that documenting it was the most
helpful...[because] then I could see how many days I’d been a
space cadet” [female, 70s].
One respondent (female, 50s) found that the app clarified some
specifics about her condition, for example, the role constipation
played in her well-being. Patients remarked on their enhanced
awareness of symptoms, for example, noting that the trial
identified issues with sleep, activity, medication use, and others.

Deciding: Drawing Conclusions and Correlations
Most patients described interacting with their tracking data such
that it moved them beyond noticing, toward drawing conclusions
and correlations from their data. One respondent (male, 50s)
said about the app, “It helps you understand the interaction
between your sleep and your pain, between your activity and
your pain.” Another patient (female, 50s) praised the app’s
tracking function, saying it made her “sit and think about it. I
guess just make you pause...think about your day. What you
did. How it felt. Those things, on a daily basis, I think is a useful
exercise in pain management.”
Similarly, another patient (female, 50s) described enhanced
self-awareness leading to better pain management:
It definitely helped me pay attention to what was
helping alleviate my pain. It felt like I was more
mindful.
One patient (male, 60s) said, "It [tracking] just triggered me to
start looking at my overall health." Several patients spoke of
the conclusions and correlations they drew from their data:
"[The app] helped me draw my own conclusions [male, 30s].
Patients had varied reactions to different pieces of their data.
One respondent (male, 50s), on being asked what was most
influential in coming to a treatment decision, suggested that the
trial results were less important “It was more the fact that I was
actually entering and writing down.” Another respondent (male,
50s) was also enthusiastic about the graphs of daily symptom
reports within the app, stating the following:
Cool thing about the app and these graphs is it helps
you understand the interaction between your sleep
and your pain, your activity and your pain. Between
your pain and your social life and your work life and
your home life.
About the collected data, another (female, 40s) said “It validated
what I kind of already knew inside.” However, several patients,
particularly those who felt more confusion about what graphs
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I was also accountable when I wrote notes when I
would say I didn’t do this or I didn’t do that or if that
increased my fatigue...it made me think about what
could be causing some other things and if I needed
to address it.
Another respondent (male, 50s) stated that symptom report
graphs were valuable and reinforced a changed approach,
I [used to] let it [pain] peak too much. Now I’ve
gotten it down, and I can really tell by the graph.
Some patients described further steps in self-management.
Patients used data to identify triggers they subsequently worked
to avoid or data that motivated improved attention to activity
or socializing. Patients made alterations in the dose, frequency,
and other aspects of treatment regimens. One patient said:
“It [data from the app] let me play around with do I
need one [medication dose], do I need to take two,
do I need to take ‘em six hours apart, do I need to
take ‘em eight hours apart.” [female, 50s]
Another (male, 50s) echoed this, having tracked his dose
response:
In terms of dosage and the frequency, it allowed me
to experiment with how much I was taking and how
often I was taking it in terms of dealing with that pain.
A few patients revealed highly independent decisions about
their treatment approaches. When asked if he had a sense from
summary data that one treatment in the N-of-1 trial was better
than another, one patient (male, 70s) answered:
Yeah, mine...I mean, I don’t know if they would accept
that for an answer, but door number three, that I came
up with, worked better...The last half of the trial, I
was on Plan C [his own plan].
Another (male, 50s) said “It [viewing the summary data via the
app] helped me decide going forward my next strategy.”
Many patients reported on their own analyses of their data. One
respondent (male, 40s) commented on using the app to “not
give me the answer but give it [data] to me so I can say ‘ok,
mmm...’.”
Another patient (male, 30s) spoke at length about using data
independently:
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It was good for me to be able to correlate things even
before there was some sort of analysis presented to
me.
However, this same patient also said of the summary analyses
[E]ven though it’s my own information and I’m
putting it into it [the app], having it presented that
way [in summary graphs] back to me was helpful.
This patient suggested an increased level of patient use of data:
I think making that app available to–or I mean, could
you make that app available to people just to use on
their own–I don’t know–to present that monthly
analysis of something like that to where they could
do their own?...[D]raw my own conclusions about
what was going on with my health.

Discussion
Principal Findings
As is true in qualitative research, these results are not
representative, but rather illustrate issues for discovery and
discussion. Our findings from a consecutive sample of the
intervention group in a randomized controlled trial examining
smartphone-enabled N-of-1 trials for chronic pain (The
PREEMPT Study) reinforced previous findings about patient
enthusiasm for access to their own PGHD and benefits to N-of-1
trial participation that included increased awareness of
symptoms [9,10,14-16].
Participants demonstrated clear preference for simple
presentations of summary data. Although few studies have
reported on patient preferences for data presentation in the
N-of-1 trial context, previous studies examining patient
preferences for the presentation of risk-benefit information have
similarly found that patients often prefer more simplistic data
presentations [17,18]. However, there is a variability in what
patients consider “simple” or “understandable.” Respondents
in our study were eager to personalize the content and display
of their PGHD within the app in the way that made the most
sense to them. Tait et al (2012) found that patients who were
given risk-benefit information that matched their preferred data
visualization format (eg, if their preferred format was a
pictograph, the information was presented to them as a
pictograph) not only reported greater satisfaction with
information but also interpreted it with significantly greater
accuracy [19]. As clinicians and health systems work toward
shared health decision making and improved chronic condition
management, they may find it important to assess patients’
preferred styles of data presentation. In future use of their own
PGHD, patients might use their preferred method of tracking
symptoms and receiving comparative treatment trial results.
With appropriate cautions about overinterpreting data, patients
could be provided with presentations of data most useful and
motivating to them.
Although our research group was concerned about the tradeoff
between accuracy and simplicity of statistical results, no patients
expressed similar concerns. We might assume that our
respondents did not fully understand statistical uncertainty, but
we did not test our patients’ knowledge nor did we teach a
http://mhealth.jmir.org/2018/10/e10291/
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primer on statistical interpretation. Future N-of-1 studies might
incorporate these additions. Some patients expressed confusion
about the meaning of statistical summary data, and almost all
expressed a preference for simplicity of results. In the primary
study, 23% of N-of-1 trials completed (22/95) did result in
significant statistical differences in treatment regimens (ie, a
95% credible interval that excluded the null value) [20]. The
research team was concerned that patients would confuse
statistical and clinical significance, perceiving greater clinical
meaning from lesser statistical difference, especially in trials
in which the difference was not significant. Those concerns
were borne out during interviews when patients reported that
summary graphs with the most information about effect size
and statistical uncertainty were the least helpful for decision
making. Instead, patients appeared primarily concerned with
finding any differences between treatment regimens and in being
able to use data to confirm their qualitative perceptions. The
growth of patient-centered research approaches may allow for
a sophisticated development of consumer friendly data analyses
that also meet the bar for understandability and accuracy, in
particular, accurately conveying the amount of uncertainty.
We found that although patients used their data autonomously
for self-management, they also wanted to partner with their
clinicians to review the results and make decisions. A previous
study that examined clinicians’ perspectives on N-of-1 trials
revealed concerns about the potentially negative impact on the
clinician-patient relationship [7]. However, no patients in our
study reported such concerns. On the contrary, most felt that
discussing trial results with their clinicians was valuable and
important. The optimum way for clinicians and patients to share
N-of-1 trial data remains to be determined; our study only hints
at patients’ perceptions from sharing their data as well as at a
caution that clinicians too will need education about interpreting
these data.
Our study suggested that patients evaluated the tracking data
and summary data distinctively. Patients were enthusiastic about
the tracking data and somewhat less so about summaries to
which they had only brief exposure. The main study was
designed to collect daily symptom reports for the primary
purpose of comparing the effectiveness of two alternative
treatment regimens. However, qualitative analysis reported here
reveals that patients did not see the comparison function as the
only, or possibly even the main, value of their PGHD. Instead,
they appreciated the ability to track their symptoms over time
with perhaps greater motivation because an eventual comparison
was in store. This may be a case of the process having as much
or more value than the outcome alone. These findings are
consistent with those of another qualitative study, which found
that patients were primarily motivated to participate in N-of-1
trials to increase accountability for self-management and
promote behavior change rather than to compare treatments
[21].
Importantly, our study focused on chronic pain and relied on
patient self-report for the primary outcome. Because patients
were experiencing and reporting any changes in pain throughout
the trial, the final comparative effectiveness result may have
been less meaningful. Future work might explore whether
patients report more benefit from comparative effectiveness
JMIR Mhealth Uhealth 2018 | vol. 6 | iss. 10 | e10291 | p. 11
(page number not for citation purposes)

JMIR MHEALTH AND UHEALTH
results in situations where the main outcome is important to
patients, but not as easily perceived by them (ie, cholesterol and
A1C).
Some patients expressed confusion about the summary data’s
meaning, and almost all expressed preference for simple
presentations of trial results. This suggests that to engage
patients deeply in their own N-of-1 trials could mean designing
analysis strategies more transparent to patients, in addition to
being easily understood. Could patients choose analyses they
want with simple explanations of tradeoffs between
comprehensiveness and comprehensibility? One might program
different interpretations for different types of patients (eg, one
for the math phobic and another for the data enthusiast). In
addition, what ways are there to bring data analyses to patients?
Are clinical visits the optimum setting, or are there other forums
in which comparative data analysis could be viewed and
discussed? Notably, participants in our study were a fairly
educated group with about half reporting a college or graduate
degree and 58% (19/33) reporting a background in mathematics,
statistics, engineering, science, or health care. Future work might
explore whether enthusiasm for and engagement with PGHD
is similarly high in populations with less education and more

Whitney et al
limited prior experience with mathematics,
engineering, science, or health care fields.

statistics,

Although not the focus of these interviews, participants revealed
a well known, but sometimes unacknowledged, aspect of clinical
practice that patients modify and enact their own treatment
regimens. Our interviews showed a wide range of therapeutic
actions by patients, at times independently of their clinicians
and N-of-1 protocols. Like clinicians, N-of-1 trial researchers
should be aware of this and may consider adaptive designs that
would enable patients and clinicians to partner in modifying
initial trial protocols.

Conclusion
Notes and numeric data tracked and analyzed by the Trialist
app in N-of-1 trials make possible new conclusions and
decisions about both collaborative treatment and
self-management. Structured records in the app may be shared
with clinicians who weigh in with their professional input, a
conversation that might not take place without the app’s
facilitation. Patients in our study valued sharing PGHD with
clinicians, even as they also made their autonomous uses of
data. Future N-of-1 studies might consider individualized,
adaptable protocols and emphasize clarity of data presentation
to optimize shared decision making.
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